Abiopharma

🔍 SUN Weike (Director)

Company: Tron Inc. (TRON)

Report Date: 2025-08-27

Detailed Transactions and Holdings:

• Acquired 220,000,000 shares of Common Stock at $0.5 per share (Direct)
  Date: 2025-08-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 220,000,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 200,000,000 shares of Common Stock at $0.5 per share (Direct)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 420,000,000.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 220,000,000 shares of Common Stock Purchase Warrants at $0.5 per share (Derivative)
  Date: 2025-08-27 | Code: M | Expires: 2027-06-16 | Exercise: 2025-06-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 200,000,000 shares of Series B Convertible Preferred Stock at $0.5 per share (Derivative)
  Date: 2026-04-02 | Code: M | Exercise: 2025-06-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F3, F1

Footnotes:

• F1: The reported securities are held directly by Bravemorning Limited ("Bravemorning"). Mr. Weike Sun is the sole shareholder of Bravemorning and may be deemed to beneficially own the securities held by Bravemorning. On June 16, 2025, Bravemorning purchased (i) 100,000 shares of Series B Convertible Preferred Stock, convertible into 200,000,000 shares of the Registrant's common stock at a conversion price of $0.50 per share and (ii) warrants to purchase up to 220,000,000 shares of the Registrant's common stock at an exercise price of $0.50 per share (the "PIPE Warrants") with the consideration of $100,000,000 paid in the form of 365,096,845 TRX.
• F2: On August 27, 2025, Bravemorning exercised the PIPE Warrants in full and, on August 29, 2025, the Registrant issued 220,000,000 shares of Common Stock to Bravemorning. The Holder paid $110,000,000 to the Registrant in the form of 312,500,100 TRX as consideration for the issuance of these Common Stock shares.
• F3: These securities do not have an expiration date.
• F4: On April 2, 2026, the Registrant received a conversion notice from Bravemorning to convert all of its 100,000 shares of Series B Preferred Stock and, on April 2, 2026, the Registrant issued 200,000,000 shares of Common Stock to Bravemorning.